Purdue Feels The Pain With $700 Million Settlement For Misleading OxyContin Promos
This article was originally published in The Pink Sheet Daily
Executive Summary
Purdue pleads guilty to illegally promoting and selling the painkiller, ending an investigation by the U.S. Attorney’s Office in Virginia.
You may also be interested in...
Closing The Books On Purdue – And US FDA’s Policies To Control Opioids
A massive settlement of opioid litigation is intended to end the era of opioid marketing defined by OxyContin. It also like closes the books on efforts to rely on the US FDA to control the prescription abuse crisis.
Panel Abuses Purdue Over OxyContin
Tamper-resistant version would lead to more problems, say FDA advisors.
Panel Abuses Purdue Over OxyContin
Tamper-resistant version would lead to more problems, say FDA advisors.